Rocuronium

PRESENTATION:	Ampoules containing 100mg/10ml and 50mg/5ml.
INDICATION:	Second line treatment for muscle relaxation in ICU patients when atracurium supply not available or not suitable. Rocuronium is a rapid onset, intermediate non-depolarising neuromuscular blocking drug.
DOSE AND ADMINISTRATION:	ICU STANDARD INTRAVENOUS INFUSION IV loading dose: 0.6 mg/kg by rapid injection. IV infusion: Administered undiluted e.g. 500mg in a 50ml syringe. Usual maintenance doses are between 0.3 - 0.6 mg/kg/hr. For a 70kg patient, this would equate to 2.1-4.2ml/h.
CONCENTRATION:	10mg/1ml.
MONITORING:	Monitoring of neuromuscular function using train-of-four peripheral nerve stimulation, is recommended during the use of rocuronium in order to individualise dosage requirements.
STABILITY:	Physically and chemically stable for 24 hours at 25° C.
OTHER INFORMATION:	Rocuronium has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a CVC is unavailable, administer via a large peripheral vein and monitor closely.

References

1. Rocuronium bromide 100mg/10ml injection, 2013. Bowmed Ibisqus Limited. Summary of Product Characteristics. Available from: https://www.medicines.org.uk/emc/product/8758/smpc (Revision of text 28/12/23)
2. United Kingdom Clinical Pharmacy Association, 2012. Minimum Infusion Volumes. Fourth Edition.
3. Rocuronium Bromide, Injectable Medicines Guide, Medusa. Updated: April 2024. Accessed: May 2024

Title: Rocuronium	
ID:	Authors: Mairi Cromarty, Fiona Clarke, Euan Simcox
Category:	Document Version: 2.0
Status Draft/Final: Final	Review Date: May 2026
Authoriser: Lothian Critical Care QIT Editorial Group	Authorisation Date: March 2022
Date added to Intranet: March 2022	Updated: May 2024
Key Words **Comments**	